Published in J Immunol on June 01, 1983
C3b covalently bound to IgG demonstrates a reduced rate of inactivation by factors H and I. J Exp Med (1984) 1.74
Mechanism of therapeutic effect of high-dose intravenous immunoglobulin. Attenuation of acute, complement-dependent immune damage in a guinea pig model. J Clin Invest (1989) 1.25
IgG bearing covalently bound C3b has enhanced bactericidal activity for Escherichia coli 0111. J Exp Med (1985) 1.11
Monoclonal antibodies against complement 3 neoantigens for detection of immune complexes and complement activation. Relationship between immune complex levels, state of C3, and numbers of receptors for C3b. J Clin Invest (1985) 1.01
Formation of C3-IgG complexes in serum by aggregated IgG and by non-immunoglobulin activators of complement. Immunology (1987) 0.81
Complement-component-C3-opsonized immunoglobulin G anti-DNA antibodies do not bind effectively to red blood cells unless aggregated on a high-Mr DNA matrix. Biochem J (1984) 0.77
Interactions of monomeric IgG bearing covalently bound C3b with polymorphonuclear leucocytes. Immunology (1987) 0.75
Characterization of a soluble cytoplasmic antigen reactive with sera from patients with systemic lupus erythmatosus. J Immunol (1969) 4.45
Autoimmune-associated congenital heart block: demographics, mortality, morbidity and recurrence rates obtained from a national neonatal lupus registry. J Am Coll Cardiol (1998) 3.68
Purification and partial characterization of a nucleolar scleroderma antigen (Mr = 34,000; pI, 8.5) rich in NG,NG-dimethylarginine. J Biol Chem (1985) 3.60
Characterization of a soluble nuclear ribonucleoprotein antigen reactive with SLE sera. J Immunol (1971) 3.59
Physical association of two nuclear antigens and mutual occurrence of their antibodies: the relationship of the SM and RNAprotein (MO) systems in SLE sera. J Immunol (1973) 3.07
Heterogeneity of RNA protein antigens reactive with sera of patients with systemic lupus erythematosus. Description of a cytoplasmic nonribosomal antigen. Arthritis Rheum (1974) 2.99
Use of glutaraldehyde as a coupling agent for proteins and peptides. Methods Enzymol (1980) 2.73
Anti-Ro (SS-A) and anti-La (SS-B) in patients with Sjögren's syndrome. Arthritis Rheum (1986) 2.39
Amino acid substitution and the antigenicity of globular proteins. Adv Immunol (1975) 2.32
Serological findings in patients with "ANA-negative" systemic lupus erythematosus. Medicine (Baltimore) (1981) 2.27
Serologic and HLA associations in subacute cutaneous lupus erythematosus, a clinical subset of lupus erythematosus. Ann Intern Med (1982) 2.26
Heterogeneity of precipitating antibodies in polymyositis and dermatomyositis. Characterization of the Jo-1 antibody system. Arthritis Rheum (1980) 2.23
Correlation of a precipitin reaction to an RNAprotein antigen and a low prevalence of nephritis in patients with systemic lupus erythematosus. N Engl J Med (1972) 2.12
Anti-DNA antibody idiotypes in systemic lupus erythematosus. Lancet (1984) 2.08
Molecular properties of the Ro/SSA antigen and enzyme-linked immunosorbent assay for quantitation of antibody. J Clin Invest (1984) 1.90
Molecular cloning, expression, and chromosome 19 localization of a human Ro/SS-A autoantigen. J Clin Invest (1990) 1.64
The association between Mi-2 antibodies and dermatomyositis. Arthritis Rheum (1985) 1.62
Clinical and serological differences between systemic lupus erythematosus patients with antibodies to Ro versus patients with antibodies to Ro and La. J Clin Invest (1982) 1.58
Anti-threonyl-tRNA synthetase, a second myositis-related autoantibody. J Exp Med (1984) 1.54
Autoantibodies of neonatal lupus erythematosus. J Invest Dermatol (1994) 1.53
The autoantibody response to Ro/SSA in cutaneous lupus erythematosus. Arch Dermatol (1994) 1.53
Significance of histologic patterns of glomerular injury upon long-term prognosis in severe lupus glomerulonephritis. Kidney Int (2001) 1.52
The clinical significance of autoantibodies to a soluble cytoplasmic antigen in systemic lupus erythematosus and other connective tissue diseases. J Rheumatol (1979) 1.51
The presence of masked antiribosomal P autoantibodies in healthy children. Arthritis Rheum (1998) 1.51
Factors predictive of outcome in severe lupus nephritis. Lupus Nephritis Collaborative Study Group. Am J Kidney Dis (2000) 1.50
A distinctive autoantibody profile in black female patients with lupus nephritis. Arthritis Rheum (1993) 1.50
Gene interaction at HLA-DQ enhances autoantibody production in primary Sjögren's syndrome. Science (1986) 1.50
Twenty percent of biopsy specimens from sun-exposed skin of normal young adults demonstrate positive immunofluorescence. Arch Dermatol (1991) 1.47
Two Ro (SS-A) autoantibody responses in systemic lupus erythematosus. Correlation of HLA-DR/DQ specificities with quantitative expression of Ro (SS-A) autoantibody. Arthritis Rheum (1988) 1.47
Pseudocyst of the auricle. J Dermatol Surg Oncol (1993) 1.46
Visual resolution and contour interaction in the fovea and periphery. Vision Res (1979) 1.42
A cost-effectiveness analysis of OKT3 induction therapy in cadaveric kidney transplantation. Am J Kidney Dis (1996) 1.42
Heterogeneity of the Ro/SSA antigen. Different molecular forms in lymphocytes and red blood cells. J Clin Invest (1989) 1.41
Familial aggregation and linkage analysis of autoantibody traits in pedigrees multiplex for systemic lupus erythematosus. Genes Immun (2006) 1.39
Autoantibodies to the ribosomal P proteins react with a plasma membrane-related target on human cells. J Clin Invest (1992) 1.37
A model for disease heterogeneity in systemic lupus erythematosus. Relationships between histocompatibility antigens, autoantibodies, and lymphopenia or renal disease. Arthritis Rheum (1989) 1.37
Problems in differentiating SLE and mixed connective-tissue disease. N Engl J Med (1976) 1.36
Economic impact of hospitalizations for lower abdominal adhesiolysis in the United States in 1988. Surg Gynecol Obstet (1993) 1.35
Reference sera for antinuclear antibodies. I. Antibodies to native DNA, Sm, nuclear RNP, and SS-B/La. Arthritis Rheum (1982) 1.33
Description of a serological reaction characteristic of polymyositis. Clin Immunol Immunopathol (1976) 1.30
Antibodies to a nuclear/nucleolar antigen in patients with polymyositis overlap syndromes. J Clin Immunol (1984) 1.30
Current perspectives on serological reactions in SLE patients. Clin Exp Immunol (1981) 1.28
The cost of hepatitis A infections in American adolescents and adults in 1997. Hepatology (2000) 1.27
Deposition of antibodies to a soluble cytoplasmic antigen in the kidneys of patients with systemic lupus erythematosus. Arthritis Rheum (1979) 1.26
Idiotypic cross-reactivity between antibodies of different specificities. J Exp Med (1978) 1.24
Significance of the Ro antigen system. J Clin Immunol (1986) 1.22
Immunological activity of cytochrome c. 3. Enhancement of antibody detection and immune response initiation by cytochrome c polymers. J Biol Chem (1970) 1.20
A mammalian tRNAHis-containing antigen is recognized by the polymyositis-specific antibody anti-Jo-1. Nucleic Acids Res (1983) 1.19
Anti-Ro(SS-A) autoantibodies in central nervous system disease associated with Sjögren's syndrome (CNS-SS): clinical, neuroimaging, and angiographic correlates. Neurology (1994) 1.19
Quantitation of precipitating antibodies to certain soluble nuclear antigens in SLE. Arthritis Rheum (1977) 1.18
The reactions of antibodies with hemeprotein antgens. The measurement of reaction kinetics and stoichiometry by fluorescence quenching. J Biol Chem (1969) 1.16
Immunological activity of cytochrome c. I. Precipitating antibodies to monomeric vertebrate cytochromes c. J Biol Chem (1970) 1.14
Antibodies to cytoplasmic antigens in lupus erythematosus. Serologic marker for systemic disease. Arthritis Rheum (1977) 1.13
An assessment of the iPad as a testing platform for distance visual acuity in adults. BMJ Open (2013) 1.12
Autoantibodies to the Ro/SSA antigen are conformation dependent. I: Anti-60 kD antibodies are mainly directed to the native protein; anti-52 kD antibodies are mainly directed to the denatured protein. Autoimmunity (1992) 1.12
Heterogeneity of the Ro/SSA antigen and autoanti-Ro/SSA response: evidence of the four antigenically distinct forms. Clin Exp Immunol (1990) 1.11
Antinuclear and anti-single-stranded DNA antibodies in morphea and generalized morphea. Arch Dermatol (1987) 1.11
Studies on the chymotrypsin C and papain fragments of human immunoglobulin M. Biochemistry (1969) 1.11
Implications of anti-Ro/Sjögren's syndrome A antigen autoantibody in normal sera for autoimmunity. J Clin Invest (1987) 1.10
Homozygous C2 deficiency, lupus erythematosus, and anti-Ro (SSA) antibodies. Arthritis Rheum (1983) 1.08
Economic value to parents of reducing the pain and emotional distress of childhood vaccine injections. Pediatr Infect Dis J (2001) 1.08
Increased frequencies of Sm and nRNP autoantibodies in American blacks compared to whites with systemic lupus erythematosus. J Rheumatol (1988) 1.08
Reference sera for antinuclear antibodies. II. Further definition of antibody specificities in international antinuclear antibody reference sera by immunofluorescence and western blotting. Arthritis Rheum (1997) 1.07
Multiplicity of antibodies in myositis sera. Arthritis Rheum (1984) 1.05
Autoantibodies to ribosomal P proteins penetrate into live hepatocytes and cause cellular dysfunction in culture. J Immunol (1997) 1.05
Immunological activity of cytochrome c. II. Localization of a major antigenic determinant of human cytochrome c. J Biol Chem (1970) 1.05
Shared early autoantibody recognition events in the development of anti-Sm B/B' in human lupus. Scand J Immunol (1999) 1.05
Antigenic structure of sperm whale myoglobin. I. Partition of specificities between antibodies reactive with peptides and native protein. J Immunol (1982) 1.04
Localizing antigenic determinants in human haemoglobin with mutants: molecular correlations of immunological tolerance. J Mol Biol (1972) 1.04
Nucleolar localization of the PM-Scl antigen. Arthritis Rheum (1985) 1.03
Acute renal failure secondary to interstitial lupus nephritis. Arch Intern Med (1978) 1.02
Antibodies against cytochromes c from vertebrates. J Biol Chem (1966) 1.02
Anti-La/SSB antibody is present in some normal sera and is coincident with anti-Ro/SSA precipitins in systemic lupus erythematosus. J Rheumatol (1984) 1.01
Interference of rheumatoid factor activity by aspartame, a dipeptide methyl ester. J Mol Recognit (2000) 1.01
Radioimmunoassay of serum myoglobin in polymyositis and other conditions. Arthritis Rheum (1977) 1.01
Key elements of the BMP/SMAD pathway co-localize with CDX2 in intestinal metaplasia and regulate CDX2 expression in human gastric cell lines. J Pathol (2008) 1.01
Systemic lupus erythematosus and intestinal venulitis. Gastroenterology (1981) 1.01
Genetic studies of Ro (SS-A) and La (SS-B) autoantibodies in families with systemic lupus erythematosus and primary Sjögren's syndrome. Arthritis Rheum (1989) 1.00
Antibodies to carbonic anhydrase in systemic lupus erythematosus and other rheumatic diseases. Arthritis Rheum (1992) 1.00
The Jo-1 antibody system in myositis: relationships to clinical features and HLA. J Rheumatol (1982) 0.99
Linear scleroderma. Clinical spectrum, prognosis, and laboratory abnormalities. Ann Intern Med (1986) 0.99
Haemolytic anaemia in a multi-ethnic cohort of lupus patients: a clinical and serological perspective. Lupus (2008) 0.98
The occurrence of shared idiotypic specificity among the goat antibodies that distinguish human hemoglobin S from A. J Immunol (1974) 0.98
Differences in the fine specificity of anti-Ro (SS-A) in relation to the presence of other precipitating autoantibodies. Arthritis Rheum (1989) 0.98
Concomitant development of chronic active hepatitis and antibodies to ribosomal P proteins in a patient with systemic lupus erythematosus. Arthritis Rheum (1993) 0.97
Influence of age on the multifocal electroretinography. Ophthalmic Physiol Opt (1999) 0.97
Anti-Ro in Sjögren's syndrome and systemic lupus erythematosus. Rheum Dis Clin North Am (1992) 0.97
Long-term follow-up of autoantibody profiles in black female lupus patients and clinical comparison with Caucasian and Asian patients. Br J Rheumatol (1997) 0.97
Patterns of clinical disease associated with antibodies to nuclear ribonucleoprotein. J Rheumatol (1978) 0.97
Clinical and immunological significance of antibodies to Ro and La in systemic lupus erythematosus. Arthritis Rheum (1982) 0.97
Anti-tissue antibodies in rheumatic disease: standardization and nomenclature. Arthritis Rheum (1977) 0.97
Antibody to Jo-1 in polymyositis/dermatomyositis: association with interstitial pulmonary disease. J Rheumatol (1984) 0.96
Measurement of antibody to Jo-1 by ELISA and comparison to enzyme inhibitory activity. J Immunol (1987) 0.96
Unmasking of anti-ribosomal P autoantibodies in healthy individuals. J Immunol (1995) 0.96
A preliminary report of acuity and contour interactions across the amblyope's visual field. Vision Res (1979) 0.96
Antibodies to Ro(SSA) and the heterogeneity of systemic lupus erythematosus. J Rheumatol Suppl (1987) 0.95
Effect of defocus on visual acuity as measured by source and observer methods. Optom Vis Sci (1989) 0.95
Properties of goat anti-human hemoglobin antibodies fractionated on subunit affinity columns. Immunochemistry (1976) 0.95
Nuclear deposits of immunoglobulins in skin of patients with systemic lupus erythematosus. Clin Exp Immunol (1977) 0.95
Presence of anti-La autoantibody is associated with a lower risk of nephritis and seizures in lupus patients. Lupus (2007) 0.94